Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets (2016 - 2025)

Amphastar Pharmaceuticals has reported Other Non-Current Assets over the past 13 years, most recently at $31.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $31.1 million for Q4 2025, up 19.79% from a year ago — trailing twelve months through Dec 2025 was $31.1 million (up 19.79% YoY), and the annual figure for FY2025 was $31.1 million, up 19.79%.
  • Other Non-Current Assets for Q4 2025 was $31.1 million at Amphastar Pharmaceuticals, up from $29.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for AMPH hit a ceiling of $31.1 million in Q4 2025 and a floor of $7.2 million in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $21.9 million (2022), compared with a mean of $21.0 million.
  • Biggest five-year swings in Other Non-Current Assets: soared 286.7% in 2021 and later fell 6.47% in 2024.
  • Amphastar Pharmaceuticals' Other Non-Current Assets stood at $16.7 million in 2021, then grew by 25.15% to $20.9 million in 2022, then grew by 24.23% to $25.9 million in 2023, then increased by 0.32% to $26.0 million in 2024, then increased by 19.79% to $31.1 million in 2025.
  • The last three reported values for Other Non-Current Assets were $31.1 million (Q4 2025), $29.9 million (Q3 2025), and $28.1 million (Q2 2025) per Business Quant data.